Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023Accesswire • 05/02/23
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual MeetingAccesswire • 04/17/23
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/29/23
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business UpdatesAccesswire • 03/29/23
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023Accesswire • 03/24/23
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)Accesswire • 01/10/23
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/02/22
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateAccesswire • 11/02/22
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220Accesswire • 11/01/22
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022Accesswire • 10/26/22
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment ConferenceAccesswire • 09/08/22
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERSAccesswire • 08/24/22
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/04/22
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAccesswire • 08/04/22
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022Accesswire • 07/28/22
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/18/22
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment ConferenceAccesswire • 05/18/22
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)Zacks Investment Research • 05/16/22
Pieris Pharmaceuticals, Inc (PIRS) CEO Stephen S. Yoder on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateAccesswire • 05/11/22